Klinik Araştırma
BibTex RIS Kaynak Göster

Serum Asprosin Levels in Patients with Hashimoto’s Thyroiditis

Yıl 2025, Cilt: 47 Sayı: 3, 352 - 357, 02.05.2025
https://doi.org/10.20515/otd.1602772

Öz

Asprosin is an orexigenic hormone secreted by adipose tissue, known to stimulate appetite. This study aimed to explore the relationship between appetite reduction, a commonly observed symptom in hypothyroidism, and serum asprosin levels, while also investigating potential metabolic implications beyond appetite regulation.We compared serum asprosin levels in 28 patients with hypothyroidism secondary to newly diagnosed Hashimoto's thyroiditis and 16 healthy controls. Additionally, serum asprosin levels were reassessed after patients achieved a euthyroid state following levothyroxine treatment, to evaluate any potential changes in relation to thyroid hormone normalization.There was no significant difference in serum asprosin levels between hypothyroid patients and healthy controls. No statistically significant difference was found between serum asprosin levels and thyroid function status. The serum asprosin levels were 4.8 ± 1.2 ng/mL in the hypothyroid group and 4.9 ± 1.1 ng/mL in the euthyroid group (p = 0.89). Furthermore, no significant change in asprosin levels was observed following levothyroxine treatment, compared to pre-treatment levels, suggesting that asprosin levels are not directly influenced by thyroid function.Ghrelin, an orexigenic hormone, is typically low in hypothyroid patients, contributing to reduced appetite. However, our study did not observe a similar decrease in asprosin levels in these patients. This suggests that, unlike ghrelin, asprosin may not be significantly affected by hypothyroidism or its treatment. Additionally, the lack of change in asprosin levels after treatment raises questions about its role in broader metabolic processes, beyond appetite regulation.The findings suggest no significant relationship between hypothyroidism and serum asprosin levels, indicating that asprosin may not play a central role in appetite reduction in hypothyroid patients.

Kaynakça

  • 1. Krzysztof Walczak and Lucyna Sieminska. Obesity and Thyroid Axis. Int. J. Environ. Res. Public Health 2021, 18, 9434.
  • 2. Patrícia de Fátima dos Santos Teixeira, Patrícia Borges dos Santos and Carmen Cabanelas Pazos-Moura. The role of thyroid hormone in metabolism and metabolic syndrome. Ther Adv Endocrinol Metab 2020, Vol. 11: 1–33
  • 3. KauShik kar, Satwika Sinha. Variations of Adipokines and Insulin Resistance in Primary Hypothyroidism. Journal of Clinical and Diagnostic Research. 2017 Aug, Vol-11(8): BC07-BC09.
  • 4. McConnell RJ, Menendez CE, Smith FR, Henkin RI, Rivlin RS. Defects of taste and smell in patients with hypothyroidism. Am J Med. 1975 Sep;59(3):354-64.
  • 5. Signe Gjedde, Esben Thyssen Vestergaard, Lars Christian Gormsen, Anne Lene Dalkjær Riis, Jørgen Rungby, Niels Møller, et al. Serum Ghrelin Levels Are Increased in Hypothyroid Patients and Become Normalized by L-Thyroxine Treatment. J Clin Endocrinol Metab, June 2008, 93(6):2277–2280.
  • 6. Mahmoud Ali Kaykhaei, Avadan Ghezel, Alireza Ansari-Moghaddam, Mahnaz Sandoughi, Vahid Sheikhi and Zahra Heidari. Changes in serum levels of Apo AIV in patients with newly diagnosed hyperthyroidism and hypothyroidism: a preliminary study. Horm Mol Biol Clin Investig. 2021 Jan 27;42(2):175-181.
  • 7. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14. PMID: 27087445; PMCID: PMC4852710.
  • 8. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017 Dec;23(12):1444-1453. doi: 10.1038/nm.4432. Epub 2017 Nov 6. PMID: 29106398; PMCID: PMC5720914.
  • 9. Yuan M, Li W, Zhu Y, Yu B and Wu J (2020) Asprosin: A Novel Player in Metabolic Diseases. Front. Endocrinol. 11:64.
  • 10. Kader Ugur and Suleyman Aydin. Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. International Journal of Endocrinology Volume 2019, Article ID 2521096, 8 pages
  • 11. Altinova AE, Toruner F, Karakoc A, Yetkin I, Ayvaz G, Cakir N, et al. Serum Ghrelin Levels in patients with Hashimoto's thyroiditis. Thyroid. 2006 Dec;16(12):1259-64. 12. Mogulkoc R, Dasdelen D, Baltaci SB, Baltaci AK, Sivrikaya A. The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats. Horm Mol Biol Clin Investig. 2020 Dec 14;42(1):37-42.
  • 13. Hassan HJ, Hameed EK, Mohammad TU. Asprosin: the potential player in combined double diabetes and hypothyroidism. Ir J Med Sci. 2024 Dec;193(6):2915-2921.

Hashimoto Tiroiditi Olan Hastalarda Serum Asprosin Düzeylerinin araştırıllması

Yıl 2025, Cilt: 47 Sayı: 3, 352 - 357, 02.05.2025
https://doi.org/10.20515/otd.1602772

Öz

Asprosin, yağ dokusu tarafından salgılanan, iştahı uyaran bir hormondur. Bu çalışmanın amacı, hipotiroidizmde yaygın olarak gözlemlenen iştah azalması semptomu ile serum asprosin düzeyleri arasındaki ilişkiyi incelemek ve ayrıca iştah düzenlemesinin ötesinde metabolik etkilerini araştırmaktır.
Hipotiroidizm tanısı almış 28 Hashimoto tiroiditi hastası ile 16 sağlıklı kontrol grubunun serum asprosin düzeyleri karşılaştırıldı. Ayrıca, hastaların levotiroksin tedavisi sonrası ötiroid duruma ulaşmalarının ardından serum asprosin düzeyleri yeniden değerlendirilerek, tiroid hormonlarının normale dönmesiyle ilişkili herhangi bir değişiklik olup olmadığı incelendi.Hipotiroidizm hastaları ile sağlıklı kontrol grubunun serum asprosin düzeyleri arasında anlamlı bir fark gözlemlenmedi. Hipotiroid grup serum asprosin düzeyleri 4.8 ± 1.2 ng/mL, ötroid grup serum asprosin düzeyleri ise 4.9 ± 1.1 ng/mL olarak saptanmıştır (p = 0.89). Ayrıca, levotiroksin tedavisi sonrası serum asprosin düzeylerinde, tedavi öncesi seviyelere kıyasla belirgin bir değişiklik görülmedi. Bu durum, asprosin düzeylerinin doğrudan tiroid fonksiyonlarından etkilenmediğini göstermektedir.Hipotiroid hastalarında iştahı azaltan bir oreksijenik hormon olan ghrelin genellikle düşüktür. Ancak, bu çalışmamızda asprosin düzeylerinde benzer bir azalma gözlemlenmemiştir. Bu durum, asprosin'in ghrelin'den farklı olarak hipotiroidizm veya tedavisinden önemli ölçüde etkilenmediğini düşündürmektedir. Ayrıca, tedavi sonrası asprosin düzeylerinde herhangi bir değişiklik gözlenmemesi, bu hormonun iştah düzenlemesinin ötesinde daha geniş metabolik süreçlerdeki rolü hakkında soru işaretleri oluşturmuştur.Elde edilen bulgular, hipotiroidizm ile serum asprosin düzeyleri arasında anlamlı bir ilişki bulunmadığını ve asprosin'in hipotiroid hastalarında iştah azalmasında merkezi bir rol oynamadığını göstermektedir.

Kaynakça

  • 1. Krzysztof Walczak and Lucyna Sieminska. Obesity and Thyroid Axis. Int. J. Environ. Res. Public Health 2021, 18, 9434.
  • 2. Patrícia de Fátima dos Santos Teixeira, Patrícia Borges dos Santos and Carmen Cabanelas Pazos-Moura. The role of thyroid hormone in metabolism and metabolic syndrome. Ther Adv Endocrinol Metab 2020, Vol. 11: 1–33
  • 3. KauShik kar, Satwika Sinha. Variations of Adipokines and Insulin Resistance in Primary Hypothyroidism. Journal of Clinical and Diagnostic Research. 2017 Aug, Vol-11(8): BC07-BC09.
  • 4. McConnell RJ, Menendez CE, Smith FR, Henkin RI, Rivlin RS. Defects of taste and smell in patients with hypothyroidism. Am J Med. 1975 Sep;59(3):354-64.
  • 5. Signe Gjedde, Esben Thyssen Vestergaard, Lars Christian Gormsen, Anne Lene Dalkjær Riis, Jørgen Rungby, Niels Møller, et al. Serum Ghrelin Levels Are Increased in Hypothyroid Patients and Become Normalized by L-Thyroxine Treatment. J Clin Endocrinol Metab, June 2008, 93(6):2277–2280.
  • 6. Mahmoud Ali Kaykhaei, Avadan Ghezel, Alireza Ansari-Moghaddam, Mahnaz Sandoughi, Vahid Sheikhi and Zahra Heidari. Changes in serum levels of Apo AIV in patients with newly diagnosed hyperthyroidism and hypothyroidism: a preliminary study. Horm Mol Biol Clin Investig. 2021 Jan 27;42(2):175-181.
  • 7. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14. PMID: 27087445; PMCID: PMC4852710.
  • 8. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017 Dec;23(12):1444-1453. doi: 10.1038/nm.4432. Epub 2017 Nov 6. PMID: 29106398; PMCID: PMC5720914.
  • 9. Yuan M, Li W, Zhu Y, Yu B and Wu J (2020) Asprosin: A Novel Player in Metabolic Diseases. Front. Endocrinol. 11:64.
  • 10. Kader Ugur and Suleyman Aydin. Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. International Journal of Endocrinology Volume 2019, Article ID 2521096, 8 pages
  • 11. Altinova AE, Toruner F, Karakoc A, Yetkin I, Ayvaz G, Cakir N, et al. Serum Ghrelin Levels in patients with Hashimoto's thyroiditis. Thyroid. 2006 Dec;16(12):1259-64. 12. Mogulkoc R, Dasdelen D, Baltaci SB, Baltaci AK, Sivrikaya A. The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats. Horm Mol Biol Clin Investig. 2020 Dec 14;42(1):37-42.
  • 13. Hassan HJ, Hameed EK, Mohammad TU. Asprosin: the potential player in combined double diabetes and hypothyroidism. Ir J Med Sci. 2024 Dec;193(6):2915-2921.
Toplam 12 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Endokrinoloji
Bölüm ORİJİNAL MAKALELER / ORIGINAL ARTICLES
Yazarlar

Sami Bahçebaşı 0000-0003-0909-7024

Hilal Sipahioğlu 0000-0002-7884-2094

Merve Elmaağaç 0000-0003-1458-0117

Sibel Kuzugüden 0000-0003-1478-5200

Yayımlanma Tarihi 2 Mayıs 2025
Gönderilme Tarihi 17 Aralık 2024
Kabul Tarihi 25 Şubat 2025
Yayımlandığı Sayı Yıl 2025 Cilt: 47 Sayı: 3

Kaynak Göster

Vancouver Bahçebaşı S, Sipahioğlu H, Elmaağaç M, Kuzugüden S. Serum Asprosin Levels in Patients with Hashimoto’s Thyroiditis. Osmangazi Tıp Dergisi. 2025;47(3):352-7.


13299        13308       13306       13305    13307  1330126978